The DNA Sequencing Facility was approved and funded by the NCI Core Grant in 1994. The Facility received """"""""excellent"""""""" merit at that time. Dr. Haig Kazazian, Chair of Genetics, has served as Facility Director since the inception of this Shared Resource. Dr. Kazazian is a well-known human molecular geneticist who had directed the Genetic Resources Core at Johns Hopkins for five years prior to coming to Penn. The Technical Director of the Facility is Dr. Tapan Ganguly. Dr. Ganguly has over 10 years of experience in cell and molecular biology, and was associated with the genetic Diagnostic Laboratory in Penn's Department of Genetics for three years before assuming this position. During the current project period, the DNA Sequencing Facility has become fully operationalized and well accepted as a major research service to Cancer Center investigators . Usage has grown consistently, with an increase of 14% from 1997 to 1998 alone. New equipment has been purchased in order to meet increasing demand. Additionally, the core has relocated to larger space in order to accommodate its increasing needs. Lastly, automated plasmid purification has been added to the core's service offerings. 53% of total usage is by Cancer Center members, while 34% is by Cancer Center members with peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-25
Application #
6300094
Study Section
Project Start
2000-02-04
Project End
2000-11-30
Budget Start
Budget End
Support Year
25
Fiscal Year
2000
Total Cost
$276,694
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Crisalli, Lisa M; Hinkle, Joanne T; Walling, Christopher C et al. (2018) Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. Biol Blood Marrow Transplant 24:1203-1208
Mazaleuskaya, Liudmila L; Salamatipour, Ashkan; Sarantopoulou, Dimitra et al. (2018) Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS. J Lipid Res 59:564-575
Facompre, Nicole D; Harmeyer, Kayla M; Sahu, Varun et al. (2018) Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget 9:8985-8998
Rosenfeld, Aaron M; Meng, Wenzhao; Chen, Dora Y et al. (2018) Computational Evaluation of B-Cell Clone Sizes in Bulk Populations. Front Immunol 9:1472
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
Fraietta, Joseph A; Lacey, Simon F; Orlando, Elena J et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563-571
Anton, Lauren; Sierra, Luz-Jeannette; DeVine, Ann et al. (2018) Common Cervicovaginal Microbial Supernatants Alter Cervical Epithelial Function: Mechanisms by Which Lactobacillus crispatus Contributes to Cervical Health. Front Microbiol 9:2181
Williams, Austin D; Reyes, Sylvia A; Arlow, Renee L et al. (2018) Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged Ann Surg Oncol 25:2875-2883
Krump, Nathan A; Liu, Wei; You, Jianxin (2018) Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol 32:71-79
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5

Showing the most recent 10 out of 1047 publications